F Vincenti

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation
    F Vincenti
    Transplant Service, University of California, San Francisco, CA, USA
    Am J Transplant 7:1770-7. 2007
  2. doi request reprint Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients
    S Busque
    Stanford University School of Medicine, Stanford, CA, USA
    Am J Transplant 9:1936-45. 2009
  3. doi request reprint Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients
    F Vincenti
    University of California, San Francisco, Kidney Transplant Service, San Francisco, CA, USA
    Am J Transplant 12:210-7. 2012
  4. doi request reprint A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)
    F Vincenti
    Kidney Transplant Service, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 10:535-46. 2010
  5. ncbi request reprint Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation
    F Vincenti
    University of California, San Francisco, USA
    Transplantation 71:1282-7. 2001
  6. ncbi request reprint Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus
    F Vincenti
    University of California San Francisco Kidney Transplant Service, San Francisco, CA, USA
    Am J Transplant 7:1506-14. 2007
  7. doi request reprint A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients
    F Vincenti
    University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 8:307-16. 2008
  8. pmc The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation
    J A Bluestone
    Diabetes Center, Department of Medicine, University of California San Francisco, CA, USA
    Am J Transplant 8:2086-96. 2008
  9. doi request reprint Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year
    F Vincenti
    University of California, San Francisco, USA
    Am J Transplant 12:2446-56. 2012
  10. ncbi request reprint Living donor kidney transplant recipients and clinical trials: participation profiles and impact on post-transplant care
    T V Brennan
    Department of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, California, USA
    Am J Transplant 6:2429-35. 2006

Detail Information

Publications22

  1. ncbi request reprint A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation
    F Vincenti
    Transplant Service, University of California, San Francisco, CA, USA
    Am J Transplant 7:1770-7. 2007
    ..The two doses of efalizumab resulted in comparable saturation and modulation of CD11a. This phase II trial suggests that efalizumab may warrant further investigation in transplantation...
  2. doi request reprint Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients
    S Busque
    Stanford University School of Medicine, Stanford, CA, USA
    Am J Transplant 9:1936-45. 2009
    ..At 15 mg BID, the efficacy/safety profile was comparable to the tacrolimus control group, excepting a higher rate of viral infection. Further dose-ranging evaluation of CP-690,550 is warranted...
  3. doi request reprint Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients
    F Vincenti
    University of California, San Francisco, Kidney Transplant Service, San Francisco, CA, USA
    Am J Transplant 12:210-7. 2012
    ..Belatacept-treated patients maintained a high rate of patient and graft survival that was comparable to cyclosporine-treated patients, despite an early increased occurrence of acute rejection and PTLD...
  4. doi request reprint A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)
    F Vincenti
    Kidney Transplant Service, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 10:535-46. 2010
    ..Belatacept was associated with superior renal function and similar patient/graft survival versus cyclosporine at 1 year posttransplant, despite a higher rate of early acute rejection...
  5. ncbi request reprint Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation
    F Vincenti
    University of California, San Francisco, USA
    Transplantation 71:1282-7. 2001
    ....
  6. ncbi request reprint Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus
    F Vincenti
    University of California San Francisco Kidney Transplant Service, San Francisco, CA, USA
    Am J Transplant 7:1506-14. 2007
    ..The incidence of NODAT or IFG at 6 months post-transplant is significantly lower with CsA-ME than with tacrolimus without a significant difference in short-term outcome...
  7. doi request reprint A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients
    F Vincenti
    University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 8:307-16. 2008
    ....
  8. pmc The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation
    J A Bluestone
    Diabetes Center, Department of Medicine, University of California San Francisco, CA, USA
    Am J Transplant 8:2086-96. 2008
    ....
  9. doi request reprint Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year
    F Vincenti
    University of California, San Francisco, USA
    Am J Transplant 12:2446-56. 2012
    ..Tofacitinib was equivalent to CsA in preventing acute rejection, was associated with improved renal function and less chronic allograft histological injury, but had side-effects at the doses evaluated...
  10. ncbi request reprint Living donor kidney transplant recipients and clinical trials: participation profiles and impact on post-transplant care
    T V Brennan
    Department of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, California, USA
    Am J Transplant 6:2429-35. 2006
    ..Overall graft and patient survival were comparable. We conclude that clinical trial participants were disproportionately male, had increased intensity of post-transplant care but comparable outcomes to nonparticipants...
  11. ncbi request reprint Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis
    J M Yabu
    Department of Medicine, University of California, San Francisco, CA, USA
    Am J Transplant 8:222-7. 2008
    ..None of the patients treated with rituximab achieved remission in proteinuria, and one patient experienced early graft loss. In these four adult renal transplant patients with recurrent FSGS, rituximab failed to diminish proteinuria...
  12. ncbi request reprint New monoclonal antibodies in renal transplantation
    F Vincenti
    Kidney Transplant Service, University of California, San Francisco, CA 94143 0780, USA
    Minerva Urol Nefrol 55:57-66. 2003
    ....
  13. ncbi request reprint Optimizing the use of cyclosporine (Neoral) for recipients of living donor kidneys
    F Vincenti
    Kidney Transplant Service, University of California San Francisco, San Francisco, CA 94143 0780, USA
    Transplant Proc 36:50S-53S. 2004
  14. ncbi request reprint Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation
    F Vincenti
    Kidney Transplant Service, UCSF, San Francisco, California 94143, USA
    Transplant Proc 37:1001-4. 2005
    ..At 3 months, median GFR (Nankivell) was 63.7 mL/min; median serum creatinine was 137 micromol/L. Full complete results are expected in December 2005...
  15. doi request reprint What's next in the pipeline
    F Vincenti
    University of California, San Francisco, Kidney Transplant Service, San Francisco, CA, USA
    Am J Transplant 8:1972-81. 2008
    ..The preclinical pipeline is not only full but promises to address previously neglected targets and fulfill unmet medical needs in transplant therapeutics...
  16. ncbi request reprint De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco
    F Vincenti
    University of California, San Francisco, Kidney Transplant Service, San Francisco, California, USA
    Transplant Proc 35:183S-186S. 2003
    ..This steroid-free maintenance regimen has been used in the last 30 enteric-drained, simultaneous pancreas-kidney transplants. Using this immunosuppressive approach, rejection rates are less than 10% for either the kidney or the pancreas...
  17. ncbi request reprint Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study
    H Ekberg
    Lund University, Malmo, Sweden
    Am J Transplant 7:560-70. 2007
    ..4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients...
  18. ncbi request reprint Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function
    G L Bumgardner
    Department of Surgery, The Ohio State University and Medical Center, Columbus 43210-1250, USA
    Transplantation 72:642-7. 2001
    ..Graft and patient survival rates were similar between placebo- and daclizumab-treated patients with DGF...
  19. ncbi request reprint Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation
    G L Bumgardner
    Division of Transplantation, Department of Surgery, The Ohio State University and Medical Center, Columbus, Ohio 43210-1250, USA
    Transplantation 72:839-45. 2001
    ..There was no beneficial effect of daclizumab on graft survival at 3 years, but the trial was inadequately powered to detect this. Both studies showed excellent graft and patient survival at 3 years...
  20. doi request reprint Tolerance versus immunosuppression: a perspective
    P F Halloran
    Am J Transplant 8:1365-6. 2008
  21. doi request reprint Open letter to the FDA: new drug trials must be relevant
    F Vincenti
    Am J Transplant 8:733-4. 2008
  22. ncbi request reprint Infliximab in the treatment of steroid-dependent ulcerative colitis
    A Armuzzi
    Department of Internal Medicine, Gemelli Hospital, Catholic University of Rome Italy
    Eur Rev Med Pharmacol Sci 8:231-3. 2004
    ..Limited and contrasting data are available on effectiveness of anti-TNF alpha therapy in ulcerative colitis. We evaluated the efficacy of infliximab in the management of steroid-dependent ulcerative colitis...